Abstract
Purpose
Diabetes mellitus, especially type II, is one of the most common chronic diseases. Its first-line oral treatment is metformin, commonly in combination with another agent such as sitagliptin, a dipeptidyl peptidase-4 inhibitor. The commercial combination is Janumet XR 50/500 mg, in which the extended-release metformin core tablet is coated with an immediate-release layer of sitagliptin. However, the coating process with solvents and a high temperature might affect the sitagliptin properties and product quality. Hence, the present study aimed to develop bilayer matrix tablets incorporating both drugs into two separate layers, a sustained-release metformin layer, and an immediate-release sitagliptin layer.
Methods
Wet granulation and direct compression methods were used for the metformin and sitagliptin layer, respectively. The optimal formulation was selected and characterized based on the design of experiments method. In vitro release and in vivo bioequivalence studies were also conducted to compare with the reference Janumet XR 50/500 mg.
Results
The optimized formulation immediately released sitagliptin (> 95%) within 30 min at pH 1.2 and sustained the release metformin for 10 h at pH 6.8. The in vivo behaviors of the bilayer tablets were bioequivalent to the commercial product, Janumet XR 50/500 mg.
Conclusion
The bilayer tablets could provide an alternative approach for combination therapy of type II diabetes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ballav C, Gough SCL (2013) Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes 6:25–37. https://doi.org/10.4137/CMED.S7314
Bonde SL, Bhadane RP, Gaikwad A, Narendiran AS, Srinivas B (2013) A simple and sensitive method for determination of metformin and sitagliptin in human plasma using liquid chromatography and tandem mass spectrometry. Int J Pharm Pharm Sci 5(3):463–470
FDA (2013) Bioanalytical method validation guidance for industry. Rockville, MD, USA, pp 1–27
Gao P, Skoug JW, Nixon PR, Ju TR, Stemm NL, Sung KC (1996) Swelling of hydroxypropyl methylcellulose matrix tablets. 2. Mechanistic study of the influence of formulation variables on matrix performance and drug release. J Pharm Sci 85(7):732–740. https://doi.org/10.1021/js9504595
Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50(2):81–98. https://doi.org/10.2165/11534750-000000000-00000
Gumieniczek A, Berecka A, Mroczek T, Wojtanowski K, Dąbrowska K, Stępień K (2019) Determination of chemical stability of sitagliptin by LC-UV, LC-MS and FT-IR methods. J Pharm Biomed Anal 164:789–807. https://doi.org/10.1016/j.jpba.2018.11.023
Hamed R, Al Baraghthi T, Sunoqrot S (2018) Correlation between the viscoelastic properties of the gel layer of swollen HPMC matrix tablets and their in vitro drug release. Pharm Dev Technol 23(9):838–848. https://doi.org/10.1080/10837450.2016.1257022
Hemanth KG, Jaganathan K, Sambath KR, Perumal P (2012) Formulation and in vitro evaluation of bilayer floating tablets of metformin hydrochloride and sitagliptin phosphate. Int J Adv Pharm 2:64–81
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J (2020) Epidemiology of type 2 diabetes-global burden of disease and forecasted trends. J Epidemiol Glob Health 10(1):107–111. https://doi.org/10.2991/jegh.k.191028.001
Migoya EM, Miller JL, Gutierrez M, Zheng W, Johnson-Levonas AO, Liu Qi, Matthews CZ, Wagner JA, Gottesdiener KM (2010) Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, Crossover Study. Clin Drug Investig 30(12):855–866. https://doi.org/10.1007/BF03256914
Park J-B, Lim J, Kang C-Y, Lee B-J (2013) Drug release-modulating mechanism of hydrophilic hydroxypropylmethylcellulose matrix tablets: distribution of atoms and carrier and texture analysis. Curr Drug Deliv 10(6):732–741. https://doi.org/10.2174/156720181006131125155652
Pedacchia A, Adrover A (2015) Swelling kinetics of HPMC tablets. Chem Eng Commun 202(7):876–884. https://doi.org/10.1080/00986445.2014.891509
Prathima SM, Chaitanya N (2013) Formulation and evaluation of sitagliptin phosphate and metformin hydrochloride trilayered tablets. Int J Drug Del 5:15–27
Pujari PS, Uttekar PS, Chaudhari PD, Bamane PS (2016) Formulation development and evaluation of bilayer floating tablet of antidiabetic drugs. Pharm Lett 8(21):34–54
Reddy S, Ahmed I, Ahmad I, Mukhopadhyay A, Thangam S (2015) Development and validation of a method for simultaneous estimation of metformin and sitagliptin in human plasma by LC-MS-MS and its application in a bioequivalence study. J Chromatogr Sci 53(9):1549–1556. https://doi.org/10.1093/chromsci/bmv055
Rena G, Pearson ER, Sakamoto K (2013) Molecular mechanism of action of metformin: old or new insights? Diabetologia 56(9):1898–1906. https://doi.org/10.1007/s00125-013-2991-0
Shah PA, Shah JV, Sanyal M, Shrivastav PS (2016) LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. J Pharm Biomed Anal 131:64–70. https://doi.org/10.1016/j.jpba.2016.08.011
Stofella NCF, Veiga A, Oliveira LJ, Montin EF, Andreazza IF, Carvalho Filho MAS et al (2019) Solid-state characterization of different crystalline forms of sitagliptin. Materials (basel) 12(15):2351. https://doi.org/10.3390/ma12152351
WHO. Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed 18 Nov 2020
Acknowledgements
The authors express sincere thanks to the Department of Science and Technology, Ho Chi Minh City and the Sapharcen for their helpful support.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
All authors (N.N.T. Nguyen, D.T. Pham, D.T. Nguyen, and T.T.L. Trinh) declare that they have no conflict of interest.
Statement of human and animal rights
This article does not contain any studies with human and animal subjects performed by any of the authors.
Informed consent
The study protocol was approved by the institutional review board of the Ethics Committee of the National Institute of Drug Quality Control (IRB No. IRB-VN01061). Informed consent was confirmed by the IRB.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Nguyen, N.N.T., Pham, D.T., Nguyen, D.T. et al. Bilayer tablets with sustained-release metformin and immediate-release sitagliptin: preparation and in vitro/in vivo evaluation. J. Pharm. Investig. 51, 579–586 (2021). https://doi.org/10.1007/s40005-021-00533-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40005-021-00533-z